Fresenius Medical Care Stock News

Renal Replacement Therapy Market The renal replacement therapy market was valued at USD 923.4 million in 2019 and is expected to grow with a CAGR of 7.4%. Renal replacement therapy was introduced in the late 1970s. Burton introduced the term hemofiltration in 1976 and conducted the

Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been given a 56.00 ($63.64) price objective by stock analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday, Borsen Zeitung reports. FME has been the topic of several other reports. Barclays set a 73.00 ($82.95) price target on shares []

Fresenius Medical's (FMS) latest dialyzer is expected to better serve dialysis patients because of its design.

Fresenius Medical's (FMS) latest dialyzer is expected to better serve dialysis patients because of its design.

The Ambulatory Infusion Pumps Telematics is a medical device used to deliver fluids into a patient''s body in a controlled manner. Some infusion pumps are designed mainly for stationary use at a patient''s bedside. When considering the use, there are

Crossmark Global Holdings Inc. cut its holdings in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 14.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,226 shares of the companys stock after selling 5,794 shares during the quarter. Crossmark []

HDs emphasis on construction pros tips the scales. Also, Wall Street opinions on Cisco Systems, Sportradar Group, Activision Blizzard, PNC Financial Services, and Fresenius Medical Care.

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have been given a consensus recommendation of Hold by the twenty ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation and five have issued a buy recommendation []

The global Dialyzer market was valued at 6243.06 Million USD in 2020 and will grow with a CAGR of 6.33% from 2021 to 2027. The global dialyzer market is being driven by a considerable increase in the geriatric population and

Curative Biotechnology (NASDAQ:CUBT) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership. Profitability This table compares Curative Biotechnology and Fresenius Medical Care AG []

DBMR has added a new report titled Iron Deficiency Injectable Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. The credible report comprises of the market

(RTTNews) - Fresenius Medical Care AG & Co. KGaA will cut around 500 to 750 jobs in Germany as part of its recently announced plan of 5,000 job cuts worldwide, report said. The dialysis company, which suffers from cost pressure and the consequences of the corona pandemic, earlier said it expects to reduce the annual costs by 500 million euros

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock analysts at Jefferies Financial Group decreased their FY2021 earnings estimates for shares of Fresenius Medical Care AG & Co. KGaA in a research report issued to clients and investors on Thursday, November 11th. Jefferies Financial Group analyst J. Vane-Tempest now expects that the company will []